Amish Prasad, DO
Cardiovascular Disease · Las Vegas, NVNPI 1194955021
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (53.6%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 47 manufacturers reported payments, led by ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) at 39.4% of the total. Among cardiovascular disease clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 648 payments — averaging $89.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$23K
- Medtronic$8K
- Abiomed$5K
- Abbott$5K
- Cvrx, Inc.$4K
- Penumbra, Inc.$2K
- plus $12K from 41 others
Across 1 payment — averaging $124.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abiomed$124
What the payments were for
- Consulting fees$1,7503%
- Speaking & faculty fees$20,25035%
- Travel & lodging$4,6918%
- Food & beverage$30,95154%
- Education$870%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LifeVest$21,248
- Impella$3,325
- Barostim Neo System$3,080
- Indigo System$1,811
- CARDIOMEMS$1,446
- CardioMEMS HF System$981
- Reveal LINQ$674
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$560
- VERQUVO$498
- LINQ II$495
- VYNDAQEL$464
- Attain$443
- Confirm Rx$434
- COREVALVE EVOLUT R$424
- UPTRAVI$387
- OPSUMIT$387
- AMPLATZER AMULET$280
- Micra$269
- XARELTO$250
- NEXLIZET$250
How this compares
$57,729 in reported general payments places this provider in the 95th percentile of 165 cardiovascular disease providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 16 | $589,439 |
| EliquisApixaban | 180 | $227,088 |
| XareltoRivaroxaban | 62 | $85,381 |
| Repatha SureclickEvolocumab | 81 | $79,019 |
| MultaqDronedarone Hcl | 38 | $51,689 |
| EntrestoSacubitril/Valsartan | 31 | $48,190 |
| JardianceEmpagliflozin | 23 | $29,535 |
| FarxigaDapagliflozin Propanediol | 25 | $23,638 |
| Repatha PushtronexEvolocumab | 16 | $17,349 |
| Ezetimibe | 44 | $1,103 |
| Metoprolol Succinate | 71 | $950 |
| Nifedipine ErNifedipine | 18 | $936 |
| Atorvastatin Calcium | 177 | $779 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 44 | $608 |
| Losartan Potassium | 79 | $465 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $869 | $816,527196 claims |
| Johnson & JohnsonXarelto | $573 | $85,38162 claims |
| Sanofi-aventis U.S. LLCMultaq | $65 | $51,68938 claims |
| NovartisEntresto | $1,083 | $48,19031 claims |
| Boehringer IngelheimJardiance | $181 | $29,53523 claims |
| AstraZenecaFarxiga | $450 | $23,63825 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 165 cardiovascular disease providers in Nevada.
Other cardiovascular disease in Las Vegas
- Arjun GururajLas Vegas$399K
- Branavan UmakanthanLas Vegas$109K
- Jawad KianiLas Vegas$73K
- Chowdhury AhsanLas Vegas$41K
- Sanjay MalhotraLas Vegas$41K
- William ReshLas Vegas$39K
- Ali NamaziLas Vegas$38K
- Herbert Cordero YordanLas Vegas$38K
- Alfred DanielianLas Vegas$30K
- Dalia HawwassLas Vegas$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.